1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 Jun 2024
Admin
News Article

GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2

Overview

Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients.

Focus of the Collaboration

The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors.
Quanqi (125SER), as a domestically marketed human Interleukin-2, is primarily used in the treatment of solid tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer, etc.
Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients.

About Grit

Grit is a clinical stage cell therapy company leading the tumor infiltrating lymphocytes (TILs) therapy development in China.
Grit's non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial -- it is the fastest TIL pipeline in China and plans for BLA filing in 2025.
Quangang Pharmaceutical is a leading domestic biopharmaceutical company dedicated to the research and development of genetic medicines, boasting GMP facilities and a specialized biotechnology research institute.
Both parties have rich technical expertise and product development experience, along with a strong reputation and influence in the biopharmaceutical field in China.

Through this collaboration, GRIT will leverage its extensive experience in T cell therapy to expedite the advancement and commercialization of cell therapy products, providing a broader range of options and instilling hope for a greater number of solid tumor patients in the Chinese market. Both parties affirm that through their joint efforts, there is anticipation for a broader spectrum of Chinese patients to soon gain access to advanced and efficacious T-cell treatment options with the affordable local IL-2 product.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!